莫西沙星与阿奇霉素治疗成人支原体肺炎的临床有效性研究  

Clinical Efficacy of Moxifloxacin and Azithromycin in the Treatment of Adult Mycoplasma Pneumonia

作　　者：王宏杰 WANG Hongjie(Department of Infectious Diseases,Affiliated Hospital of Chifeng University,Songshan,Chifeng,024005 China)

机构地区：[1]赤峰学院附属医院感染性疾病科,赤峰松山024005

出　　处：《世界复合医学》2022年第8期183-186,191,共5页World Journal of Complex Medicine

摘　　要：目的对比分析成人支原体肺炎患者接受莫西沙星以及阿奇霉素治疗产生的临床效果。方法选取2019年6月—2021年6月赤峰学院附属医院收治的120例成人支原体肺炎患者作为研究对象,以随机抽签的方式分为对照组(应用阿奇霉素治疗,60例)和观察组(应用莫西沙星治疗,60例),比较两组疗效。结果观察组治疗后肺功能指标第1秒用力呼气量(2.48±0.33)L、最大呼吸流量(190.33±5.78)L、用力肺活量(2.78±0.54)L均高于对照组,差异有统计学意义(t=5.298、10.710、6.217,P<0.05);观察组治疗后肺部阴影消失时间(7.09±2.65)d、退热时间(2.10±0.46)d、咳嗽消失时间(4.25±1.33)d、住院时间(3.28±1.08)d均短于对照组,差异有统计学意义(t=6.867、10.687、11.288、4.486,P<0.05);观察组临床治疗总有效率96.67%高于对照组,差异有统计学意义(χ^(2)=5.925,P<0.05);观察组不良反应发生率3.33%明显低于对照组,差异有统计学意义(χ^(2)=6.987,P<0.05)。结论利用莫西沙星对成人支原体肺炎患者实施临床医治,可以显著缩短症状消失时间,改善肺功能指标,提升治疗有效率,同时不良反应发生率更低,因此与阿奇霉素治疗效果相比效果更优。Objective To compare and analyze the clinical effects of moxifloxacin and azithromycin in adult patients with mycoplasma pneumonia.Methods 120 adult patients with mycoplasma pneumonia admitted to the Affiliated Hospital of Chifeng University from June 2019 to June2021 were selected as the research objects.They were divided into the control group(azithromycin treatment,60 cases)and the observation group(moxifloxacin treatment,60 cases)by random lottery.The curative effects of the two groups were compared.Results After treatment,the pulmonary function indexes of forced expiratory volume in the first second(2.48±0.33)L,maximum respiratory flow(190.33±5.78)L and forced vital capacity(2.78±0.54)L in the observation group were higher than those of the control group,and the difference was statistically significant(t=5.298,10.710,6.217,P<0.05).The disappearance time of lung shadow(7.09±2.65)d,fever reduction time(2.10±0.46)d,cough disappearance time(4.25±1.33)d and hospitalization time(3.28±1.08)d after treatment in the observation group were all shorter than those in the control group,and the difference was statistically significant(t=6.867,10.687,11.288,4.486,P<0.05).The total effective rate of observation group was 96.67%higher than that of the control group,and the difference was statistically significant(χ^(2)=5.925,P<0.05).The incidence of adverse reactions in the observation group was 3.33%,lower than that of the control group,and the difference was statistically significant(χ^(2)=6.987,P<0.05).Conclusion The clinical treatment of adult mycoplasma pneumonia patients with moxifloxacin can significantly shorten the time of symptom disappearance,improve pulmonary function indicators,and improve the efficiency of treatment.At the same time,the incidence of adverse reactions is lower,so the effect is better than that of azithromycin.

关 键 词：成人支原体肺炎 阿奇霉素 莫西沙星 治疗效果 

分 类 号：R4[医药卫生—临床医学]